(Q34593046)

English

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

1 reference

10.1186/1741-7015-11-193

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1186/1741-7015-11-193

author name string

Clifford J Bailey

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jorge L Gross

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Delphine Hennicken

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Nayyar Iqbal

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Traci A Mansfield

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

James F List

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

20 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606470

7 July 2018

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606470

7 July 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606470

7 July 2018

Association between serum uric acid and development of type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606470

7 July 2018

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606470

7 July 2018

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606470

7 July 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606470

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606470

7 July 2018

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-43

21 January 2018

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-43

21 January 2018

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-43

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-43

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-43

21 January 2018

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-43

21 January 2018

Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-43

21 January 2018

Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-43

21 January 2018

Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23425012

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1741-7015-11-43

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34593046&oldid=2196842636"